We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Offers Opinions on BsUFA II Interim Assessment
Industry Offers Opinions on BsUFA II Interim Assessment
In public comments, industry trade associations have largely welcomed the FDA’s efforts thus far to improve its process for reviewing and approving biosimilars under the Biosimilar User Fee Amendments (BsUFA) II program.